RBC Capital Comments on BioMarin (BMRN) Following Prosensa (RNA) Deal

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. SAP
6. CSX
7. LRCX
8. LVS
9. QGEN
10. SPY

Go back to RBC Capital Comments on BioMarin (BMRN) Following Prosensa (RNA) Deal

BioMarin Pharma (BMRN) to Acquire Prosensa (RNA) for $17.75/Share

November 24, 2014 6:01 AM EST

BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) and Prosensa Holding N.V. (Nasdaq: RNA) announced that they have entered into a definitive agreement in which BioMarin will offer to purchase all of the outstanding ordinary shares of Prosensa for $17.75 per share, for a total up front consideration of approximately $680 million. In addition, two approximately $80 million contingent milestones are payable for the approval of drisapersen in the U.S. no later than May 15, 2016 and Europe no later than February 15, 2017, respectively.

"BioMarin is dedicated to the rare disease community, and the acquisition... More